AR120887A1 - Uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv - Google Patents

Uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv

Info

Publication number
AR120887A1
AR120887A1 ARP200103631A ARP200103631A AR120887A1 AR 120887 A1 AR120887 A1 AR 120887A1 AR P200103631 A ARP200103631 A AR P200103631A AR P200103631 A ARP200103631 A AR P200103631A AR 120887 A1 AR120887 A1 AR 120887A1
Authority
AR
Argentina
Prior art keywords
respiratory syncytial
syncytial virus
immunogenic formulation
virus protein
protein against
Prior art date
Application number
ARP200103631A
Other languages
English (en)
Inventor
Parra Alexis Kalergis
Ramrez Susan Bueno
Muoz Pablo Gonzalez
Original Assignee
Univ Pontificia Catolica Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pontificia Catolica Chile filed Critical Univ Pontificia Catolica Chile
Publication of AR120887A1 publication Critical patent/AR120887A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere al uso de una formulación inmunogénica que contiene la cepa Bacilo de Calmette y Guerin (BCG) en una concentración entre 10⁴ - 10⁹ bacterias, que expresan al menos una proteína o fragmento inmunogénico del virus respiratorio sincicial (VRS, Human orthopneumovirus), en una solución tampón salina farmacéuticamente aceptable porque sirve para preparar una vacuna útil para prevenir, tratar o atenuar infecciones de metapneumovirus humano (hMPV).
ARP200103631A 2019-12-26 2020-12-23 Uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv AR120887A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2019003847A CL2019003847A1 (es) 2019-12-26 2019-12-26 Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv

Publications (1)

Publication Number Publication Date
AR120887A1 true AR120887A1 (es) 2022-03-30

Family

ID=76573373

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103631A AR120887A1 (es) 2019-12-26 2020-12-23 Uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv

Country Status (9)

Country Link
US (1) US20230055706A1 (es)
EP (1) EP4082566A4 (es)
JP (1) JP2023508505A (es)
CN (1) CN115023238A (es)
AR (1) AR120887A1 (es)
CL (1) CL2019003847A1 (es)
MX (1) MX2022008036A (es)
PE (1) PE20221731A1 (es)
WO (1) WO2021127797A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2020002568A1 (es) * 2020-10-05 2022-08-05 Univ Pontificia Catolica Chile Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002710A1 (es) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
CL2013002829A1 (es) * 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
CN108348593B (zh) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗

Also Published As

Publication number Publication date
MX2022008036A (es) 2022-08-22
EP4082566A1 (en) 2022-11-02
EP4082566A4 (en) 2024-03-13
PE20221731A1 (es) 2022-11-07
JP2023508505A (ja) 2023-03-02
WO2021127797A1 (es) 2021-07-01
CN115023238A (zh) 2022-09-06
CL2019003847A1 (es) 2021-08-06
US20230055706A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
MX2022005990A (es) Formulaciones de anticuerpos anti-c5 de alta concentracion.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
CL2011002634A1 (es) Disolucion acuosa sin alcohol etilico que comprende propanolol o una sal farmaceuticamente aceptable del mismo, un edulcorante tipo no azucarado y menos del 0,01 % (p/v) de un agente conservante; procedimiento de preparacion; uso de la disolucion en el tratamiento de hemangiomas.
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
MX2023003199A (es) Vacuna contra la enfermedad por coronavirus de 2019 (covid-19) basada en el virus de la parainfluenza 5 (piv5).
CO2023003242A2 (es) Vacuna contra el coronavirus y procedimiento para la preparación de la misma
PE20090653A1 (es) Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc
BR112021021637A2 (pt) Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
AR120887A1 (es) Uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
MX2020008415A (es) Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg.
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
Sumathi et al. Shewanella algae: first case report of the fast emerging marine pathogen from squamous cell carcinoma patient in India
BR112021023319A2 (pt) Vetor viral
CL2013002829A1 (es) Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
CL2022003743A1 (es) Formulaciones de tableta dispersable que comprenden dolutegravir
CL2020000857A1 (es) Nuevo uso de formulación inmunogénica bcg que expresa una proteína del virus respiratorio sincicial humano contra bvrs en bovinos
BR112021020141A2 (pt) Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva
ES2670493T3 (es) Vacuna de MTB-C contra respuestas alérgicas
AR087811A1 (es) Vacuna contra el staphylococcus aureus
BR112022007253A2 (pt) Vacinas contra o vírus influenza e usos das mesmas
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero